SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aviron
AVIR 3.375+1.7%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don W Stone who wrote (177)11/14/1997 11:10:00 AM
From: Vector1  Read Replies (2) of 645
 
UPDATE

A possible competitor to Aviron' s cold-adapted influenza virus vaccine announced negative Phase II results. The following is a summary of a Robby Stephens report I reviewed today.
----
Pasteur Merieux Connaught and Virus Research Institute (VRII $5 3/8, -3 1/2) announced preliminary Phase II results of an influenza vaccine being developed by the companies. In the Phase II study, in 430 elderly adults received a shot with either standard flu vaccine or flu vaccine plus VRII' s Adjumer. Although the companies have not disclosed details of the results, they did state that the Adjumer vaccine appears to be well tolerated. They also disclosed that the immunogenicity results (i.e., protective effects) were not as good as had been observed in a previous Phase I study. In the Phase II study, the degree of improvement in immune response in the Adjumer-treated patients was less than the improvement in the Phase I trial. Moreover, the immunogenicity in the control arm was higher in the Phase II than in the Phase I trial. The two companies are continuing to assess the Phase II results and will determine what next steps are appropriate. It is clear, however, that the development time line for Adjumer has been slowed.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News